Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
Daiichi Sankyo
2019-04-09 09:15:01
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
Daiichi Sankyo
2019-04-04 14:05:51
EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients
Daiichi Sankyo
2019-04-02 15:45:01
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
Daiichi Sankyo
2019-04-03 16:31:00
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Daiichi Sankyo
2019-03-29 10:33:04
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi
Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-Daily LIXIANA®▼ Undergoing Diagnostic or Therapeutic Procedures
Daiichi Sankyo
2019-03-20 14:03:59
Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in
CLEAR Wisdom Demonstrated First-in-Class, Oral, Once-daily, ACL inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
Daiichi Sankyo
2019-03-19 13:00:02
CLEAR Wisdom Demonstrated First-in-Class, Oral, Once-daily, ACL inhibitor Bempedoic Acid Significantly Lowered
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
Daiichi Sankyo
2019-03-18 16:00:01
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral,
Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant LDL-cholesterol lowering and reduced marker of underlying cardiovascular inflammation, with a similar tolerability to placebo
Daiichi Sankyo
2019-04-04 13:32:37
Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant
Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions at EHRA 2019, the Annual Congress of the European Heart Rhythm Association
Daiichi Sankyo
2019-04-03 11:19:18
Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions
More Stories
